Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. (Nasdaq: NOVT) is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. As a trusted technology partner to medical and advanced technology equipment manufacturers, the company frequently features in news related to its financial performance, capital markets activity, and participation in investor and industry conferences.
News about Novanta often includes quarterly earnings releases and related conference call announcements, where the company reports GAAP results alongside non-GAAP metrics such as Adjusted EBITDA, Adjusted Diluted EPS, and Organic Revenue Growth. These updates provide insight into how its precision medicine, precision manufacturing, medical solutions, robotics and automation, and advanced surgery businesses are performing.
Investors can also expect coverage of capital structure developments, such as the offering and pricing of tangible equity units that combine prepaid stock purchase contracts with senior amortizing notes, as well as amendments to credit agreements and details of senior credit facilities. Announcements about share repurchase authorizations by the Board of Directors are another recurring news theme, reflecting decisions on capital allocation.
In addition, Novanta regularly appears in conference and investor event schedules, including healthcare and industrial conferences hosted by firms such as J.P. Morgan, Baird, Jefferies, and CJS Securities. These events highlight management’s engagement with the investment community and provide forums for discussing strategy and market positioning.
This news page aggregates such items in one place, helping readers follow Novanta’s earnings announcements, financing activities, share repurchase plans, and public presentations over time.
Novanta Inc. (NASDAQ: NOVT) will release its third quarter 2022 results on November 8, 2022. A conference call is scheduled for 10:00 a.m. ET on the same day, which can be accessed by dialing (888) 346-3959 or through a live webcast on the company's website. The audio replay of the call will be available for listening approximately three hours post-event until January 2, 2023. Novanta specializes in advanced technology solutions for medical and industrial OEMs, focusing on precision and performance.
Novanta reported a strong second quarter in 2022 with GAAP revenue of $215.4 million, a 29% increase year-over-year. Consolidated net income reached $17.5 million, reflecting a 49% rise in diluted EPS to $0.49. Adjusted EPS improved by 26% to $0.78, while adjusted EBITDA was $45.0 million. With bookings up 25% year-over-year, the company raised its full-year guidance, forecasting revenue between $848 million and $852 million.
Novanta Inc. (NASDAQ: NOVT) will release its second quarter 2022 results on August 9, 2022, followed by a conference call at 10:00 a.m. ET. Interested parties can access the call by dialing (888) 346-3959 or through a live webcast on the company’s website. A replay will be available approximately three hours post-call and will remain accessible until October 3, 2022. As a leader in technology solutions for healthcare and advanced industries, Novanta enables OEMs with precision and performance in their applications.
Novanta Inc. (NASDAQ: NOVT) announced that CEO Matthijs Glastra and CFO Robert Buckley will present at the CJS Securities 22nd Annual “New Ideas” Summer Conference on July 12, 2022, in Greenwich, CT. As a leading supplier of technology solutions for medical and advanced industrial OEMs, Novanta focuses on precision technology, including photonics and motion control. The company emphasizes innovation and customer success, aiming to provide a competitive edge to its partners. For more details, visit www.novanta.com.
Novanta Inc. (Nasdaq: NOVT) announced that CFO Robert Buckley will present at Baird's 2022 Global Consumer, Technology & Services Conference on June 7, 2022, in New York, NY. Novanta is a leader in providing technology solutions for medical and advanced industrial OEMs, focusing on photonics, vision, and precision motion. Their expertise enables them to deliver high-performance core components tailored to demanding applications. For more information, visit www.novanta.com.
Novanta Inc. (NASDAQ: NOVT) announces that CFO Robert Buckley and EVP Charlie Webster will present at the William Blair 42nd Annual Growth Stock Conference on June 6, 2022, in Chicago, IL. The company is a leading global supplier of technology solutions for medical and advanced industrial OEMs, focusing on photonics, vision, and precision motion. With a commitment to innovation and customer success, Novanta engineers components that deliver precision performance tailored to demanding applications.
Novanta reported a strong first quarter 2022, with GAAP revenue rising 26% to $204 million and net income of $18.8 million. Adjusted EPS increased 26% to $0.73, while Adjusted EBITDA grew 33% to $43.6 million. Customer demand remains robust, with a record backlog of $586 million and an organic revenue growth of 7.4%. Novanta expects continued strong growth in Q2 2022, with revenue guidance of $205 million to $213 million despite macroeconomic challenges.
Celera Motion, a unit of Novanta, announced new sizes and capabilities for its Aura Absolute Chip Encoder Series. These encoders cater to high-volume OEM applications such as surgical robots and cobots. The Aura line features built-in eccentricity compensation, high resolution, and low-power consumption. New customizable scale sizes range from 18 mm to 63.5 mm for rotary and 9 mm to 195 mm for linear applications. This expansion aims to enhance precision in motion-control solutions while addressing customer demands for high performance.
Novanta Inc. (NASDAQ: NOVT) will release its first quarter 2022 results on May 10, 2022. A conference call is scheduled for 10:00 a.m. ET the same day, available via dial-in or live webcast on Novanta's investor relations page. The call will provide insights into the company's performance and strategic direction. A replay of the call will be accessible three hours afterward and will remain available until July 4, 2022. Novanta specializes in technology solutions for healthcare and advanced industrial OEMs, focusing on photonics, vision, and precision motion.
Novanta reported strong financial results for the full year 2021, with GAAP revenue of $706.8 million, a 19.7% increase from 2020, and net income of $50.3 million. The diluted EPS rose to $1.41, up from $1.25 in the previous year. In Q4 2021, revenue reached $199 million, marking a 34.9% increase year-over-year. Adjusted EBITDA was $152.7 million for the full year. Despite challenges such as supply chain disruptions, Novanta enters 2022 with a record backlog of $569 million and anticipates revenue between $825 million to $845 million.
FAQ
What is the current stock price of Novanta (NOVT)?
What is the market cap of Novanta (NOVT)?
